GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $853.46 million. The enterprise value is $1.16 billion.
| Market Cap | 853.46M |
| Enterprise Value | 1.16B |
Important Dates
The last earnings date was Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 338.68 million shares outstanding. The number of shares has decreased by -10.82% in one year.
| Current Share Class | 104.71M |
| Shares Outstanding | 338.68M |
| Shares Change (YoY) | -10.82% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 4.00% |
| Owned by Institutions (%) | 17.56% |
| Float | 91.38M |
Valuation Ratios
The trailing PE ratio is 42.50 and the forward PE ratio is 22.30.
| PE Ratio | 42.50 |
| Forward PE | 22.30 |
| PS Ratio | 1.08 |
| Forward PS | 1.08 |
| PB Ratio | 1.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.15 |
| P/OCF Ratio | 5.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.59, with an EV/FCF ratio of 6.99.
| EV / Earnings | 56.39 |
| EV / Sales | 1.47 |
| EV / EBITDA | 10.59 |
| EV / EBIT | 12.54 |
| EV / FCF | 6.99 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.47 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 4.60 |
| Debt / FCF | 3.26 |
| Interest Coverage | 2.21 |
Financial Efficiency
Return on equity (ROE) is 3.22% and return on invested capital (ROIC) is 4.58%.
| Return on Equity (ROE) | 3.22% |
| Return on Assets (ROA) | 3.48% |
| Return on Invested Capital (ROIC) | 4.58% |
| Return on Capital Employed (ROCE) | 7.95% |
| Weighted Average Cost of Capital (WACC) | 9.16% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $29,492 |
| Employee Count | 697 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $24.95 million in taxes.
| Income Tax | 24.95M |
| Effective Tax Rate | 54.83% |
Stock Price Statistics
The stock price has decreased by -36.36% in the last 52 weeks. The beta is 1.55, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -36.36% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 52.64 |
| Average Volume (20 Days) | 1,739,742 |
Short Selling Information
The latest short interest is 7.62 million, so 2.25% of the outstanding shares have been sold short.
| Short Interest | 7.62M |
| Short Previous Month | 8.32M |
| Short % of Shares Out | 2.25% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 6.03 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $787.89 million and earned $20.56 million in profits. Earnings per share was $0.06.
| Revenue | 787.89M |
| Gross Profit | 723.50M |
| Operating Income | 92.42M |
| Pretax Income | 45.51M |
| Net Income | 20.56M |
| EBITDA | 109.41M |
| EBIT | 92.42M |
| Earnings Per Share (EPS) | $0.06 |
Balance Sheet
The company has $235.71 million in cash and $541.35 million in debt, with a net cash position of -$305.64 million or -$0.90 per share.
| Cash & Cash Equivalents | 235.71M |
| Total Debt | 541.35M |
| Net Cash | -305.64M |
| Net Cash Per Share | -$0.90 |
| Equity (Book Value) | 621.99M |
| Book Value Per Share | 1.84 |
| Working Capital | 407.27M |
Cash Flow
In the last 12 months, operating cash flow was $170.33 million and capital expenditures -$4.52 million, giving a free cash flow of $165.81 million.
| Operating Cash Flow | 170.33M |
| Capital Expenditures | -4.52M |
| Depreciation & Amortization | 17.00M |
| Net Borrowing | -5.00M |
| Free Cash Flow | 165.81M |
| FCF Per Share | $0.49 |
Margins
Gross margin is 91.83%, with operating and profit margins of 11.73% and 2.61%.
| Gross Margin | 91.83% |
| Operating Margin | 11.73% |
| Pretax Margin | 5.78% |
| Profit Margin | 2.61% |
| EBITDA Margin | 13.89% |
| EBIT Margin | 11.73% |
| FCF Margin | 21.05% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 10.82% |
| Shareholder Yield | 10.82% |
| Earnings Yield | 2.41% |
| FCF Yield | 19.43% |
Analyst Forecast
The average price target for GoodRx Holdings is $3.18, which is 26.19% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.18 |
| Price Target Difference | 26.19% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 3.91% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 0.35 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.35 |
| Piotroski F-Score | 5 |